Century Financial Statements From 2010 to 2025
| IPSC Stock | USD 0.58 0.06 9.38% |
Check Century Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Century Therapeutics' main balance sheet or income statement drivers, such as , as well as many indicators such as . Century financial statements analysis is a perfect complement when working with Century Therapeutics Valuation or Volatility modules.
Check out the analysis of Century Therapeutics Correlation against competitors. Century Therapeutics Company Profit Margin Analysis
Century Therapeutics' Profit Margin measures overall efficiency of a company and shows its ability to withstand competition as well as defend against adverse conditions such as rising costs, falling prices, decline in sales or management distress. Profit margin tells investors how well the company executes on its overall pricing strategies as well as how effective the company in controlling its costs.
Current Century Therapeutics Profit Margin | (0.19) % |
Most of Century Therapeutics' fundamental indicators, such as Profit Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Century Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, Profit Margin indicator shows the amount of money the company makes from total sales or revenue. It can provide a good insight into companies in the same sector, as well as help to identify trends of a company from year to year.
| Competition |
Based on the latest financial disclosure, Century Therapeutics has a Profit Margin of -0.191%. This is 98.3% lower than that of the Biotechnology sector and 99.17% lower than that of the Health Care industry. The profit margin for all United States stocks is 84.96% lower than that of the firm.
Century Therapeutics Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Century Therapeutics's current stock value. Our valuation model uses many indicators to compare Century Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Century Therapeutics competition to find correlations between indicators driving Century Therapeutics's intrinsic value. More Info.Century Therapeutics is rated third overall in return on equity category among its peers. It is rated second overall in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Century Therapeutics' earnings, one of the primary drivers of an investment's value.About Century Therapeutics Financial Statements
Century Therapeutics stakeholders use historical fundamental indicators, such as Century Therapeutics' revenue or net income, to determine how well the company is positioned to perform in the future. Although Century Therapeutics investors may analyze each financial statement separately, they are all interrelated. For example, changes in Century Therapeutics' assets and liabilities are reflected in the revenues and expenses on Century Therapeutics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Century Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Century Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Century Therapeutics, Inc. was founded in 2018 and is headquartered in Philadelphia, Pennsylvania. Century Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 170 people.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Century Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Century Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Century Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Century Therapeutics Stock:Check out the analysis of Century Therapeutics Correlation against competitors. For information on how to trade Century Stock refer to our How to Trade Century Stock guide.You can also try the Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Century Therapeutics. If investors know Century will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Century Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Century Therapeutics is measured differently than its book value, which is the value of Century that is recorded on the company's balance sheet. Investors also form their own opinion of Century Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Century Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Century Therapeutics' market value can be influenced by many factors that don't directly affect Century Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Century Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Century Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Century Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.